Full profile
| Also known as | Neumentix, Mentha spicata |
|---|---|
| Best for | Working memory support · Attention support |
| Evidence grade | Grade C · Limited: early or small human trials |
| Studied dose range | 900 mg/day of standardized extract. |
| Time to effect | Acute attention signal within hours; working-memory benefit studied over 90 days. |
| Best form | Neumentix, standardized to roughly 14.5–24% total phenolics including rosmarinic acid. |
Evidence, honestly graded
Downgraded from B to C on 2026-07-11 for sponsor-dependence. Both supporting trials are Kemin-funded (the Neumentix developer): Herrlinger 2018 (J Altern Complement Med), a 90-day RCT in adults with age-associated memory impairment (not a broad healthy-adult population), and the Falcone 2018 follow-up acute-attention trial (PMC6291964). With no manufacturer-independent replication, a pivotal trial in the wrong population, and effect sizes near the threshold of clinical meaningfulness, the honest grade is C.
See the full grading rubric (study type, replication, population match, and dose adequacy) in The Evidence Standard.
83 natural health products with an active licence in Health Canada's LNHPD list Spearmint Extract as a medicinal ingredient.
That makes Spearmint Extract a recognized, licensable medicinal ingredient in Canada, regulated by Health Canada's Natural and Non-prescription Health Products Directorate, which issues each licensed natural health product a Natural Product Number (NPN). Search the LNHPD to verify.
Side effects
- Generally well tolerated
Who should avoid it or check first
- Pregnant or breastfeeding without clinician guidance (limited data)
Interactions
- No material known interactions
Stacks well with
What to look for on a label
- Specify the branded Neumentix extract and its phenolic standardization. Plain spearmint extract doesn't guarantee the studied material.
References
- Herrlinger 2018, J Altern Complement Med: Neumentix 90-day RCT. Adults with age-associated memory impairment; 90-day dosing improved working memory versus placebo, with a follow-up acute-attention trial. PMID 29314866. Kemin-funded; educational, not a product claim.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
Revision history
Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.
- 2026-07-11Grade changeGrade B → Grade C
Downgraded from B to C. The working-memory effect is real in the trials that exist but rests on a single branded extract with limited independent replication.
See how Spearmint Extract compares on grade, dose, and goal in the Evidence Explorer.
